Dr Jeanne Tie From Australia discusses her

In this #DocTalk, Dr. Jeanne Tie from The Walter & Eliza Hall Institute of Medical Research, Australia talks about her #ctDNA DYNAMIC II trial with Paltown Development Foundation Scientific Director, Dr. Manju George
Time Stamp
00:00: Introduction
04:29: Minimal Residual Disease
06:06: Duke’s Staging
07:11: AJCC TNM staging
07:50: Adjuvant treatment for Early stage CRC & Challenges
08:53: Things tried in Stage II Colon cancer
11:00: Better risk stratification in Stage II Colon cancer
11:59: Clinical Dilemma in Stage II Colon Cancer
13:50: Other challenges
15:55: How to move the field forward?
16:30: Circulating Tumor DNA, what is it?
18:12: CtDNA detects MRD
19:19: CtDNA dynamic reflects tumor burden in CRC
20:04: Post-op ctDNA detection and what it means
23:29: CtDNA Dynamics: Real time monitoring & its value
25:18: Serial ctDNA- what info does it provide about adj chemo?
26:35: GALAXY Trial results: Role of adj chemo?
27:50: The DYNAMIC II trial
30:00: DYNAMIC II: CtDNA assay used
31:02: DYNAMIC II: Main study results
31:35: DYNAMIC II: Additional results
32:25: DYNAMIC II: Summary
35:00: DYNAMIC III: Design
36:19: Post-treatment ctDNA, role?
37:25: Trials for CtDNA positivity after Adj treatment
40:00: Q & A

[@greenwald007]

I'd love to see information on Baseline before any treatment negative CTdna (signatera) for Rectal cancer.